⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AQST News
Aquestive Therapeutics, Inc. Common Stock
AQST INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics Ready to Announce with Confidence?
newsfilecorp.com
AQST
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight
prnewswire.com
LIVN
PTC
UCB
XENE
AQST
TAK
BHVN
KNOP
VRTX
SUPN
GSK
SNY
MD
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
globenewswire.com
AQST
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
AQST
ARDT DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on March 9, 2026 Ready to Announce with Confidence?
newsfilecorp.com
ARDT
AGL
AQST
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics Ready to Announce with Confidence?
newsfilecorp.com
AQST
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
globenewswire.com
AQST
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
globenewswire.com
AQST
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
AQST
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
globenewswire.com
AQST